Abstract
A staging hybrid F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in a 78-year-old man with bone metastases from non-small cell lung cancer (NSCLC) revealed markedly focal FDG uptake in multiple vertebrae, but without clearly visible bone metastases (a). After 4 months of oral treatment with erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor, EGFRTKI), follow-up PET/CT showed a remarkable decrease in FDG uptake in the otherwise now clearly sclerotic bone metastases (b). An osteoblastic healing response (OHR), defined as the induction of osteoblastic bone lesions and associated with
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
